United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$353.00 USD
+1.67 (0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $353.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
Brokerage Reports
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 21 - 40 ( 611 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso and DPI Lead Near-Term Growth - Considerations on Competitive Differentiation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q4/FY23: Rounding Out the Year of Tyvaso DPI w/ Another Record Revenue Quarter
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Tyvaso Near-Term Growth With TETON Program Broadening Upside; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A